» Articles » PMID: 18344185

A Statistical Methodology for Drug-drug Interaction Surveillance

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2008 Mar 18
PMID 18344185
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Interaction between drug substances may yield excessive risk of adverse drug reactions (ADRs) when two drugs are taken in combination. Collections of individual case safety reports (ICSRs) related to suspected ADR incidents in clinical practice have proven to be very useful in post-marketing surveillance for pairwise drug--ADR associations, but have yet to reach their full potential for drug-drug interaction surveillance. In this paper, we implement and evaluate a shrinkage observed-to-expected ratio for exploratory analysis of suspected drug-drug interaction in ICSR data, based on comparison with an additive risk model. We argue that the limited success of previously proposed methods for drug-drug interaction detection based on ICSR data may be due to an underlying assumption that the absence of interaction is equivalent to having multiplicative risk factors. We provide empirical examples of established drug-drug interaction highlighted with our proposed approach that go undetected with logistic regression. A database wide screen for suspected drug-drug interaction in the entire WHO database is carried out to demonstrate the feasibility of the proposed approach. As always in the analysis of ICSRs, the clinical validity of hypotheses raised with the proposed method must be further reviewed and evaluated by subject matter experts.

Citing Articles

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province.

Wang J, Zhao Y, Chen Z, Huang R Front Pharmacol. 2025; 15():1451713.

PMID: 39845792 PMC: 11751046. DOI: 10.3389/fphar.2024.1451713.


Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.

Wang S, Zhang R, Wang S, Guo Q, Yin D, Song Y Front Pharmacol. 2024; 15:1309148.

PMID: 39534085 PMC: 11555396. DOI: 10.3389/fphar.2024.1309148.


Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase).

Akagi T, Hamano H, Miyamoto H, Takeda T, Zamami Y, Ohyama K Eur J Clin Pharmacol. 2024; 81(1):129-137.

PMID: 39443366 DOI: 10.1007/s00228-024-03767-6.


Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.

Huo B, Shu L, Xiao J, Yin N, Ai M, Jia Y Front Pharmacol. 2024; 15:1292163.

PMID: 39403147 PMC: 11471622. DOI: 10.3389/fphar.2024.1292163.


Immune-Related Adverse Events due to Concomitant Use of Immune Checkpoint Inhibitors and Chinese Herbal Medicines: A Study Based on a Japanese Adverse Event Database.

Koshiishi T, Nishioka N, Yoshimoto K Asian Pac J Cancer Prev. 2024; 25(7):2291-2295.

PMID: 39068560 PMC: 11480620. DOI: 10.31557/APJCP.2024.25.7.2291.